| human | Q5 |
| P496 | ORCID iD | 0000-0002-1221-0326 |
| P3829 | Publons author ID | 2128339 |
| P1053 | ResearcherID | F-5008-2017 |
| P1153 | Scopus author ID | 6701364178 |
| P69 | educated at | University of Milan | Q46210 |
| P108 | employer | National Cancer Institute | Q3747179 |
| P735 | given name | Liliana | Q430546 |
| Liliana | Q430546 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q47763723 | Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). |
| Q39924019 | Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. |
| Q57903207 | CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) |
| Q33391725 | Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). |
| Q33414243 | Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group |
| Q50688251 | Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. |
| Q58924331 | Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP |
| Q61774245 | Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up |
| Q61774238 | Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial |
| Q45048444 | High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults |
| Q54863084 | High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. |
| Q61774247 | High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen |
| Q43490516 | High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. |
| Q58924317 | Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease |
| Q58924323 | Lack of carboplatin activity in malignant lymphomas |
| Q44166662 | Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. |
| Q42535831 | Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. |
| Q58924291 | Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience |
| Q42933017 | MALT lymphoma and Kaposi sarcoma in an HIV-negative patient |
| Q61774244 | Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia |
| Q34529373 | Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue |
| Q61774252 | Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study |
| Q33401136 | Phase II study of sorafenib in patients with relapsed or refractory lymphoma. |
| Q57903247 | Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group |
| Q42435631 | Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience |
| Q53235017 | Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo I |
| Q54481816 | Radioimmunotherapy and secondary leukemia: a case report. |
| Q48333236 | Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. |
| Q43553524 | Successful second autologous engraftment after long duration storage of hematopoietic stem cells |
| Q54083100 | The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. |
| Q45287423 | The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. |
| Q61774254 | The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies |
| Q51961830 | Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. |
Search more.